Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.
PLoS One. 2012;7(4):e36051. doi: 10.1371/journal.pone.0036051. Epub 2012 Apr 26.
MicroRNAs are small non-coding RNAs involved in the regulation of gene expression on a posttranscriptional level. These regulatory RNAs have been implicated in numerous cellular processes and are further deregulated in different cancer types, including breast cancer. MiR-92a is part of the miR-17∼92 cluster, which was first reported to be linked to tumourigenesis. However, little is known about the expression of miR-92a in breast cancer and potential associations to tumour properties. The expression of miR-92a was therefore characterized in 144 invasive breast cancer samples using in situ hybridization and related to clinico-pathological data as well as to selected key properties of the tumour stroma, including the presence of macrophages (CD68) and cancer activated fibroblasts (alpha-SMA).
METHODOLOGY/PRINCIPAL FINDINGS: To measure miR-92a levels, an in situ hybridisation protocol was developed and validated using cell lines and miR-92a inhibitors. The expression in the tumour samples was objectively evaluated using digital image analysis program subtracting background activities. We found that the miR-92a expression varied between tumours and was inversely correlated to tumour grade (r = -0.276, p = 0.003) and recurrence-free survival (p = 0.008) and provided independent prognostic information in multivariate Cox analysis (HR: 0.375, CI: 0.145-0.972, p = 0.043). MiR-92a was moreover inversely correlated to the number of infiltrating macrophages in the tumour stroma (r = -0.357, p<0.001), and downregulation of miR-92a promoted cell migration (p<0.01).
CONCLUSIONS/SIGNIFICANCE: This study demonstrates that downregulation of miR-92a in breast cancer is linked to key epithelial and stromal properties as well as clinical outcome.
microRNAs 是参与基因表达转录后调控的小非编码 RNA。这些调节 RNA 参与了许多细胞过程,并在包括乳腺癌在内的不同癌症类型中进一步失调。miR-92a 是 miR-17∼92 簇的一部分,该簇最初被报道与肿瘤发生有关。然而,miR-92a 在乳腺癌中的表达及其与肿瘤特性的潜在关联知之甚少。因此,本研究使用原位杂交技术对 144 例浸润性乳腺癌样本中的 miR-92a 表达进行了特征描述,并将其与临床病理数据以及肿瘤基质的选定关键特性相关联,包括巨噬细胞(CD68)和癌激活成纤维细胞(α-SMA)的存在。
方法/主要发现:为了测量 miR-92a 水平,开发并验证了一种原位杂交方案,使用细胞系和 miR-92a 抑制剂。使用数字图像分析程序减去背景活性来客观评估肿瘤样本中的表达。我们发现,miR-92a 的表达在肿瘤之间存在差异,并且与肿瘤分级呈负相关(r = -0.276,p = 0.003),与无复发生存率呈负相关(p = 0.008),并在多变量 Cox 分析中提供了独立的预后信息(HR:0.375,CI:0.145-0.972,p = 0.043)。miR-92a 还与肿瘤基质中浸润性巨噬细胞的数量呈负相关(r = -0.357,p<0.001),下调 miR-92a 可促进细胞迁移(p<0.01)。
结论/意义:本研究表明,乳腺癌中 miR-92a 的下调与关键的上皮和基质特性以及临床结局相关。